GARFIELD-AF model for prediction of stroke and major bleeding in atrial fibrillation: a Danish nationwide validation study. Issue 11 (11th November 2019)

• Record Type: Journal Article
• Authors: Dalgaard, Frederik; Pieper, Karen; Verheugt, Freek; Camm, A John; Fox, Keith AA; Kakkar, Ajay K; Pallisgaard, Jannik L; Rasmussen, Peter V; Weert, Henk van; Lindhardt, Tommi Bo; Torp-Pedersen, Christian; Gislason, Gunnar H; Ruwald, Martin H; Harskamp, Ralf E
• Is Part Of: BMJ open. Volume 9:Issue 11(2019)
• Publication Date: 2019-11-11
• Subjects: stroke -- cardiology -- pacing & electrophysiology; Medicine -- Research -- Periodicals; 610.72
• DOI: 10.1136/bmjopen-2019-033283
• Languages: English
• ISSNs: 2044-6055

Abstract

Abstract : Objectives: To externally validate the accuracy of the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) model against existing risk scores for stroke and major bleeding risk in patients with non-valvular AF in a population-based cohort. Design: Retrospective cohort study. Setting: Danish nationwide registries. Participants: 90 693 patients with newly diagnosed non-valvular AF were included between 2010 and 2016, with follow-up censored at 1 year. Primary and secondary outcome measures: External validation was performed using discrimination and calibration plots. C-statistics were compared with CHA2 DS2 VASc score for ischaemic stroke/systemic embolism (SE) and HAS-BLED score for major bleeding/haemorrhagic stroke outcomes. Results: Of the 90 693 included, 51 180 patients received oral anticoagulants (OAC). Overall median age (Q1, Q3) were 75 (66–83) years and 48 486 (53.5%) were male. At 1-year follow-up, a total of 2094 (2.3%) strokes/SE, 2642 (2.9%) major bleedings and 10 915 (12.0%) deaths occurred. The GARFIELD-AF model was well calibrated with the predicted risk for stroke/SE and major bleeding. The discriminatory value of GARFIELD-AF risk model was superior to CHA2 DS2 VASc for predicting stroke in the overall cohort (C-index: 0.71, 95% CI: 0.70 to 0.72 vs C-index: 0.67, 95% CI: 0.66 to 0.68, p<0.001) as well as in low-risk patients (C-index: 0.64, 95% CI: 0.59 to 0.69 vs C-index: 0.57, 95% CI: 0.53 to 0.61, p=0.007). The GARFIELD-AF model was comparable to HAS-BLED in predicting the risk of major bleeding in patients on OAC therapy (C-index: 0.64, 95% CI: 0.63 to 0.66 vs C-index: 0.64, 95% CI: 0.63 to 0.65, p=0.60). Conclusion: In a nationwide Danish cohort with non-valvular AF, the GARFIELD-AF model adequately predicted the risk of ischaemic stroke/SE and major bleeding. Our external validation confirms that the GARFIELD-AF model was superior to CHA2 DS2 VASc in predicting stroke/SE and comparable with HAS-BLED for predicting major bleeding.